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www.jacctctabstracts2013.com TUESDAY, OCTOBER 29, 2013, 3:30 PM–5:30 PMand net adverse cardiac events (25 vs. 21%, P¼0.56) were similar in the TT and
DAPT groups, respectively.
Conclusions: There does not seem to be a signiﬁcant beneﬁt of TT over DAPT in
patients with paroxysmal AF in SR undergoing PCI.P
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Background: The Antagonize P2Y12 Treatment Inhibitors by Transfusion of
platelets in an Urgent or DElayed Timing after ACS or PCI presentation (The
APTITUDE study) was designed to demonstrate the effect of ex vivo platelet
transfusion (PT) in a coronary population receiving loading doses of P2Y12 receptor
antagonists.
Methods: Patients presenting with acute coronary syndrome or for elective PCI and
receiving a loading dose of either clopidogrel 600/900mg, prasugrel 60mg or
ticagrelor 180mg were included. Blood was drawn from participants at two
different time points; just before administration of the P2Y12 inhibitor loading dose
(LD) (H0) and 4-6 hours after (H4). Transfusion was performed ex vivo by mixing
naïve platelets in the form of platelet rich plasma (PRP-H0) with PRP at H4 (PRP-
H4) in increasing proportions. The primary study endpoint was the percentage
restoration of platelet function with addition of 80% proportion of PRP H0
measured by the residual platelet aggregation (RPA) in response to 20 mM ADP
{RPA (80%/20% H0/H4 mix)/RPA baseline x 100} using light transmission
aggregometry.
Results: A total of 56 patients (76% male) half (n¼28) presenting with ACS and half
presenting for elective PCI were included. Baseline RPA did not differ signiﬁcantly
between groups (p¼0.65). Patients with poor pharmacodynamic response to the LD
administered (RPA H4>46.6%) were excluded from the ﬁnal analysis leaving 45
patients: Groups 1. clopidogrel 600mg (n ¼13) 2. clopidogrel 900mg (n¼12) 3.
prasugrel 60mg (n¼10) 4. ticagrelor 180mg (n¼10). Increasing proportions (30%,
50%, 80%) of platelet transfusion led to a stepwise increase in restoration of platelet
reactivity in all groups 1-4 (p for trend < 0.0001, 0.01, <0.0001 and 0.0052
respectively). The primary endpoint of % restoration of platelet function with 80%
proportion PT showed a stepwise decrease from groups 1 to 4 (83.911%, 7314%,
66.315%, 40.919% respectively; p for trend < 0.0001).
Conclusions: The efﬁcacy of ex vivo platelet transfusion in normalization of platelet
function appears to decrease with more potent P2Y12 receptor antagonism and to be
the least with direct P2Y12 inhibitors.
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Background: Data on direct pharmacodynamic comparison between ticagrelor and
prasugrel are limited, mainly involving speciﬁc subgroups (e.g. patients with STJACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT Abstrelevation myocardial infarction-STEMI, diabetes mellitus or high platelet reactivity
under clopidogrel).
Methods: This was a prospective, single-center study, in consecutive patients with
acute coronary syndrome (ACS), who underwent percutaneous coronary intervention
(PCI). Platelet reactivity (PR) measurement was performed 30 days after constant
treatment with ticagrelor 90mg bid or prasugrel 10mg od maintenance dose. Treatment
choice was at physicians' discretion. Bleeding events (Bleeding Academic Research
Consortium –BARC classiﬁcation) were also monitored.
Results: We recruited 384 patients (with a mean age of 59.311.1 years, 83.6% men,
24.5% diabetics and 55.7% admitted with STEMI), out of them 211 and 173 received
ticagrelor and prasugrel respectively. Demographic and angiographic characteristics of
patients were well balanced between groups. After propensity score adjustment for
gender, diabetes mellitus, smoking, creatinine clearance<60ml/min, age, hematocrit,
platelet count and body mass index, PR at 30 days was signiﬁcantly lower with
ticagrelor compared with prasugrel (34.4, 95%CIs 28.2-40.7 versus 81.9, 95%CIs
74.9-88.8, p<0.001). There was a trend towards more BARC type 1 events with
ticagrelor compared to prasugrel at 30 days (38.9% vs 29.5%, p¼0.07). However,
BARC type 2 events did not differ between ticagrelor and prasugrel (1.4% vs 2.9%,
p¼0.5).
Conclusions: In patients with ACS undergoing PCI, ticagrelor MD produces
a signiﬁcantly higher platelet inhibition compared to prasugrel MD. This observed
pharmacodynamic difference might be associated with more nuisance bleeding events
with ticagrelor use.TCT-166
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Background: Several studies have demonstrated an association between high
platelet reactivity (HPR) on clopidogrel and the risk of stent thrombosis and adverse
ischemic outcomes. We sought to determine the correlates of HPR from a large
observational study of patients undergoing routine platelet reactivity testing.
Methods: ADAPT-DES was a prospective multicenter study of pts treated with
coronary DES designed to determine the predictors of stent thrombosis. VerifyNow
P2Y12 testing was performed after clopidogrel loading in 8,583 "all-comer" pts
enrolled at 11 international sites. Linear regression of platelet reactivity units (PRU)
on baseline and procedural covariates was used to determine independent correlates of
PRU.
Results: The mean age was 63.6 years, an acute coronary syndrome was present in
51.7% of pts, and the mean PRU was 188  97. Baseline demographic charac-
teristics independently associated with higher PRU included: age, body mass index,
female sex, non-Caucasian ethnicity, diabetes, non-smoking status, prior myocar-
dial infarction, and anemia. Pre-hospital use of a thienopyridine or statin was
independently associated with higher PRU. When procedural characteristics were
examined in addition to baseline covariates, use of femoral vascular access, intra-
aortic balloon pump, and bivalirudin for anticoagulation were all independently
associated with higher PRU, as were baseline TIMI 0/1 ﬂow, total stent length, and
treatment of calciﬁc lesions. Further modeling to identify the percent contribution
of each of these covariates to the overall variance of PRU will be performed/
presented.
Conclusions: In a large unselected cohort of patients undergoing PCI with DES,
numerous independent correlates of HPR were identiﬁed, including demographic
characteristics, comorbid conditions, antecedent medications, and procedural vari-
ables. These ﬁndings illustrate the multifactorial nature of clopidogrel responsiveness
among patients undergoing PCI.acts/POSTER/Antiplatelets and Antithrombins B53
